申请人:Hoffmann-La Roche Inc.
公开号:US20160207885A1
公开(公告)日:2016-07-21
The present invention relates to compounds of formula
wherein
A is
R is lower alkyl, —(CH
2
)
z
-C
3-7
-cycloalkyl or —(CH
2
)
z
—C
4-6
-heterocycloalkyl, which are optionally substituted by one to three hydroxy, lower alkyl, lower alkoxy or halogen, or is (endo)-7-oxabicyclo[2.2.1]heptan-2-yl;
X is CH or N;
Y
1
is CR
3
or N;
Y
2
is CR
4
; or
or Y
1
and Y
2
may form together with the carbon atoms to which they are attach
Y
3
is N;
Y
4
is N;
Y
5
is NR
7
;
R
1
is hydrogen or halogen;
R
2
is hydrogen, halogen, cycloalkyl, lower alkyl or lower alkoxy;
R
3
is hydrogen, halogen,
CN, —C(O)NH
2
, —C(O)NHCH
3
or —C(O)N(CH
3
)
2
;
R
4
is hydrogen, a 5 or 6 membered heteroaryl or heterocyclyl group, selected from the group consisting of
or is phenyl, —C(O)NH
2
, —CH
2
C(O)NH
2
, —C(O)NHCH
3
, —C(O)NH-cycloalkyl, —C(O)N(CH
3
)
2
, —NHC(O)O-lower alkyl, CN, lower alkoxy, lower alkoxy substituted by halogen, halogen or S(O)
2
CH
3
;
R
5
is phenyl;
R
6
is phenyl or thiazol-2-yl;
R
7
is pyridin-2-yl or pyrimidin-4-yl;
p is 0 or 1;
m is 1, 2 or 3;
z is 0 or 1;
or a pharmaceutically acceptable acid addition salt, a racemic mixture or its corresponding enantiomer and/or optical isomers thereof.
The compounds may be used for the treatment or prophylaxis of Alzheimer's disease, cognitive impairment, schizophrenia, pain or sleep disorders.
本发明涉及以下式子的化合物:
其中,
A是
R是较低的烷基,-(CH2)z-C3-7-环烷基或-(CH2)z-C4-6-杂环烷基,可选地被一个到三个羟基,较低的烷基,较低的烷氧基或卤素取代,或是(内)-7-氧杂双环[2.2.1]庚烷-2-基;
X是CH或N;
Y1是CR3或N;
Y2是CR4;或
或Y1和Y2可以与它们所连接的碳原子一起形成;
Y3是N;
Y4是N;
Y5是NR7;
R1是氢或卤素;
R2是氢,卤素,环烷基,较低的烷基或较低的烷氧基;
R3是氢,卤素,CN,-C(O)NH2,-C(O)NHCH3或-C(O)N(CH3)2;
R4是氢,5或6成员的杂芳基或杂环基,从以下组中选择,或是苯基,-C(O)NH2,-CH2C(O)NH2,-C(O)NHCH3,-C(O)NH-环烷基,-C(O)N(CH3)2,-NHC(O)O-较低的烷基,CN,较低的烷氧基,被卤素取代的较低的烷氧基,卤素或S(O)2CH3;
R5是苯基;
R6是苯基或噻唑-2-基;
R7是吡啶-2-基或嘧啶-4-基;
p是0或1;
m是1、2或3;
z是0或1;
或其药学上可接受的酸加合物,外消旋体混合物或其对应的对映异构体。
这些化合物可用于治疗或预防阿尔茨海默病、认知障碍、精神分裂症、疼痛或睡眠障碍。